Pharmacogenomics of Gynecological Disorders
作者： Jaspreet Kaur , Beenish Rahat , Jyotdeep Kaur
DOI: 10.1007/978-81-322-1184-6_30
关键词:
摘要: Pharmacogenomics aims to identify the genome-based variability in drug disposition (metabolism and transport), which influences its efficacy toxicity, also develop diagnostics therapeutics on basis of genetic variants so as individualize pharmacotherapy. Progress made last two decades pharmacogenomics study gynecological diseases has enabled us predict therapy outcome inherited or acquired mutations. The present chapter focuses clinical relevance variation terms diagnosis, prognosis, context this group with special reference cancers. Various disease susceptibility genes their polymorphisms disorders have been identified, molecular targeted therapies developed. To name a few well studied are BRCA1/2, HER2, GSTT1, GSTM1, CYP1B1, PPAR-γ, VEGF, etc. Detailed account components associated each how it discourse individualization is given here.
springer.com
sci-hub.st 参考文章(238)
Colacurci N, Fortunato N, Mele D, Cassese S, De Seta L, De Franciscis P, Tamoxifen effects on endometrium. Panminerva Medica. ,vol. 42, pp. 45- ,(2000)
Bryn Williams-Jones, Oonagh P Corrigan, Rhetoric and Hype Where's the 'Ethics' in Pharmacogenomics? American Journal of Pharmacogenomics. ,vol. 3, pp. 375- 383 ,(2003) , 10.2165/00129785-200303060-00004
Cara M. Martin, Louise Kehoe, Cathy O. Spillane, John J. O’Leary, Gene Discovery in Cervical Cancer Molecular Diagnosis & Therapy. ,vol. 11, pp. 277- 290 ,(2007) , 10.1007/BF03256249
M D Pegram, R J Pietras, S B Howell, V R Chazin, B M Fendly, D J Slamon, Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. ,vol. 9, pp. 1829- 1838 ,(1994)
G. Konecny, M. Untch, M. Pegram, Herceptin in the treatment of metastatic breast cancer Gynakologe. ,vol. 32, pp. 624- 631 ,(1999) , 10.1007/PL00003274
Richard J. Pietras, David Gallardo, P. Nancy Wongvipat, H. Julie Lee, Joseph C. Poen, Dennis J. Slamon, Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Research. ,vol. 59, pp. 1347- 1355 ,(1999)
Jon O. Lundberg, Eddie Weitzberg, Mark T. Gladwin, The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics Nature Reviews Drug Discovery. ,vol. 7, pp. 156- 167 ,(2008) , 10.1038/NRD2466
P. Kastner, A. Krust, B. Turcotte, U. Stropp, L. Tora, H. Gronemeyer, P. Chambon, Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. The EMBO Journal. ,vol. 9, pp. 1603- 1614 ,(1990) , 10.1002/J.1460-2075.1990.TB08280.X
M Massobrio, D Katsaros, GL Scheffer, Albert Suurmeijer, M Kool, Hjg Arts, S Danese, R Arisio, de Elisabeth G. E. Vries, RJ Scheper, F Genta, Phb Willemse, van der Ate Zee, Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clinical Cancer Research. ,vol. 5, pp. 2798- 2805 ,(1999)
Rong Lin, Yunping Lei, Ziyu Yuan, Hongfang Ju, Dongna Li, Angiotensinogen gene M235T and T174M polymorphisms and susceptibility of pre-eclampsia: a meta-analysis. Annals of Human Genetics. ,vol. 76, pp. 377- 386 ,(2012) , 10.1111/J.1469-1809.2012.00722.X